eIf3a mediates malignant biological behaviors in colorectal cancer through the PI3K/AKT signaling pathway

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–11. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Pincheira R, Chen Q, Zhang JT. 2001. Identification of a 170-kDa protein over-expressed in lung cancers. Br J Cancer. 84(11):1520–1527. doi: 10.1054/bjoc.2001.1828.
   PubMed Web of Science ®Google Scholar
• Valasek L, Phan L, Schoenfeld LW, Valásková V, Hinnebusch AG. 2001. Related eIF3 subunits TIF32 and HCR1 interact with an RNA recognition motif in PRT1 required for eIF3 integrity and ribosome binding. Embo J. 20(4):891–904. doi: 10.1093/emboj/20.4.891.
   PubMed Web of Science ®Google Scholar
• Mayeur GL, Fraser CS, Peiretti F, Block KL, Hershey JWB. 2003. Characterization of eIf3k: a newly discovered subunit of mammalian translation initiation factor elF3. Eur J Biochem. 270(20):4133–4139. doi: 10.1046/j.1432-1033.2003.03807.x.
   PubMedGoogle Scholar
• Saletta F, Suryo Rahmanto Y, Richardson DR. 2010. The translational regulator eIf3a: the tricky eIF3 subunit! Biochim Biophys Acta. 1806(2):275–286. doi: 10.1016/j.bbcan.2010.07.005.
   PubMed Web of Science ®Google Scholar
• Dong Z, Zhang JT. 2006. Initiation factor eIF3 and regulation of mRNA translation, cell growth, and cancer. Crit Rev Oncol Hematol. 59(3):169–180. doi: 10.1016/j.critrevonc.2006.03.005.
   PubMed Web of Science ®Google Scholar
• Kim JT, Lee SJ, Kim BY, Lee C-H, Yeom YI, Choe Y-K, Yoon D-Y, Chae S-K, Kim JW, Yang Y, et al. 2013. Caspase-mediated cleavage and DNase activity of the translation initiation factor 3, subunit G (eIf3g). FEBS Lett. 587(22):3668–3674. doi: 10.1016/j.febslet.2013.09.027.
   PubMed Web of Science ®Google Scholar
• Haybaeck J, O’Connor T, Spilka R, Spizzo G, Ensinger C, Mikuz G, Brunhuber T, Vogetseder A, Theurl I, Salvenmoser W, et al. 2010. Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. Anticancer Res. 30(4):1047–1055.
   PubMed Web of Science ®Google Scholar
• Pastushenko I, Blanpain C. 2019. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 29(3):212–226. doi: 10.1016/j.tcb.2018.12.001.
   PubMed Web of Science ®Google Scholar
• Dong Z, Liu Z, Cui P, Pincheira R, Yang Y, Liu J, Zhang J-T. 2009. Role of eIf3a in regulating cell cycle progression. Exp Cell Res. 315(11):1889–1894. doi: 10.1016/j.yexcr.2009.03.009.
   PubMed Web of Science ®Google Scholar
• Yin JY, Zhang JT, Zhang W, Zhou H-H, Liu Z-Q. 2018. eIf3a: A new anticancer drug target in the eIF family. Cancer Lett. 412:81–87. doi: 10.1016/j.canlet.2017.09.055.
   PubMed Web of Science ®Google Scholar
• Mei C, Liu C, Gao Y, Dai W-T, Zhang W, Li X, Liu Z-Q. 2022. eIf3a regulates colorectal cancer metastasis via translational activation of RhoA and Cdc42. Front Cell Dev Biol. 10:794329. doi: 10.3389/fcell.2022.794329.
   PubMed Web of Science ®Google Scholar
• Zheng X, Wang S, Hong S, Liu J, Jiang C. 2021. Knockdown of eIf3a attenuated cell growth in K1 human thyroid cancer cells. Genes Genomics. 43(4):379–388. doi: 10.1007/s13258-021-01048-5.
   PubMed Web of Science ®Google Scholar
• Spilka R, Ernst C, Bergler H, Rainer J, Flechsig S, Vogetseder A, Lederer E, Benesch M, Brunner A, Geley S, et al. 2014. eIf3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cell Oncol (Dordr). 37(4):253–267. doi: 10.1007/s13402-014-0181-9.
   PubMed Web of Science ®Google Scholar
• Wang SQ, Liu Y, Yao MY, Jin J. 2016. Eukaryotic translation initiation factor 3a (eIf3a) promotes cell proliferation and motility in pancreatic cancer. J Korean Med Sci. 31(10):1586–1594. doi: 10.3346/jkms.2016.31.10.1586.
   PubMed Web of Science ®Google Scholar
• Miao B, Wei C, Qiao Z, Han W, Chai X, Lu J, Gao C, Dong R, Gao D, Huang C, et al. 2019. eIf3a mediates HIF1α-dependent glycolytic metabolism in hepatocellular carcinoma cells through translational regulation. Am J Cancer Res. 9(5):1079–1090.
   PubMed Web of Science ®Google Scholar
• Ding Z, Liu J, Wang J, Huang B, Zhong M. 2019. Upregulation of eukaryotic translation initiation factor 3 subunit a promotes cell survival in ameloblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 128(2):146–153. doi: 10.1016/j.oooo.2019.02.016.
   PubMed Web of Science ®Google Scholar
• Dellas A, Torhorst J, Bachmann F, B?nziger R, Schultheiss E, Burger MM. 1998. Expression of p150 in cervical neoplasia and its potential value in predicting survival. Cancer. 83(7):1376–1383. doi: 10.1002/(SICI)1097-0142(19981001)83:7<1376:AID-CNCR15>3.0.CO;2-1.
   PubMed Web of Science ®Google Scholar
• Chen G, Burger MM. 1999. p150 expression and its prognostic value in squamous-cell carcinoma of the esophagus. Int J Cancer. 84(2):95–100. doi: 10.1002/(sici)1097-0215(19990420)84:2<95:aid-ijc1>3.0.co;2-n.
   PubMed Web of Science ®Google Scholar
• Chen G, Burger MM. 2004. p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer. 112(3):393–398. doi: 10.1002/ijc.20443.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yu JJ, Tian Y, Li Z-Z, Zhang C-Y, Zhang S-F, Cao L-Q, Zhang Y, Qian C-Y, Zhang W, et al. 2015. eIf3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation. Oncotarget. 6(28):25441–25451. doi: 10.18632/oncotarget.4555.
   PubMedGoogle Scholar
• Dong Z, Zhang JT. 2003. EIF3 p170, a mediator of mimosine effect on protein synthesis and cell cycle progression. Mol Biol Cell. 14(9):3942–3951. doi: 10.1091/mbc.e02-12-0784.
   PubMed Web of Science ®Google Scholar
• Jiang N, Dai Q, Su X, Fu J, Feng X, Peng J. 2020. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 47(6):4587–4629. doi: 10.1007/s11033-020-05435-1.
   PubMed Web of Science ®Google Scholar
• Wang L, Wen X, Luan F, Fu T, Gao C, Du H, Guo T, Han J, Huangfu L, Cheng X, et al. 2019. EIF3B is associated with poor outcomes in gastric cancer patients and promotes cancer progression via the PI3K/AKT/mTOR signaling pathway. Cancer Manag Res. 11:7877–7891. doi: 10.2147/CMAR.S207834.
   PubMed Web of Science ®Google Scholar
• Zhang F, Xiang S, Cao Y, Li M, Ma Q, Liang H, Li H, Ye Y, Zhang Y, Jiang L, et al. 2017. EIF3D promotes gallbladder cancer development by stabilizing GRK2 kinase and activating PI3K-AKT signaling pathway. Cell Death Disease. 8(6):e2868. doi: 10.1038/cddis.2017.263.
   PubMedGoogle Scholar
• Hu J, Luo H, Xu Y, Luo G, Xu S, Zhu J, Song D, Sun Z, Kuang Y. 2019. The prognostic significance of EIF3C gene during the tumorigenesis of prostate cancer. Cancer Invest. 37(4–5):199–208. doi: 10.1080/07357907.2019.1618322.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang S, Li MY, Huang R, Ng CSH, Wan IYP, Long X, Wu J, Wu B, Du J, et al. 2016. Tumorigenesis of smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is related to its ability to stimulate thromboxane synthase and enhance stemness of non-small cell lung cancer stem cells. Cancer Lett. 370(2):198–206. doi: 10.1016/j.canlet.2015.10.017.
   PubMed Web of Science ®Google Scholar